• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap™ PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 20042 / SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application...

SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

1 June 2004/in 2004, News

SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2004-06-01 14:28:562016-11-28 14:29:22SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

SuperGen Provides Additional Analysis of Response Data from Phase III Study...SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin...
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok